LAUSR

Key Points Question Is dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor associated with better clinical outcomes for patients with acute coronary syndrome treated with coronary artery bypass grafting compared with ASA monotherapy? Findings In this nationwide cohort study including 6558 patients, there was no significant risk reduction in major adverse cardiovascular events (a composite of all-cause mortality, myocardial infarction, and stroke) associated with ASA plus ticagrelor treatment compared with ASA monotherapy, although the dual therapy was associated with increased risk for major bleeding. Meaning These results suggest that further research, preferably randomized clinical trials, are warranted to define optimal antiplatelet therapy in this group.